<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000560648"><TermName>methylnaltrexone</TermName><TermPronunciation>(MEH-thul-nal-TREK-sone)</TermPronunciation><TermDefinition><DefinitionText>The active ingredient in a drug used to relieve certain side effects caused by treatment with opiods (pain killers similar to morphine), such as constipation (hard, dry stools), itching, and low urine flow. Methylnaltrexone binds to opioid receptors outside the brain and may block the side effects of opioid drugs without affecting their ability to relieve pain. Methylnaltrexone is a type of peripheral opioid receptor antagonist.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000721079" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;methylnaltrexone&quot;" language="en" id="_3"/><MediaLink ref="CDR0000721080" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;metilnaltrexona&quot;" language="es" id="_4"/><SpanishTermName>metilnaltrexona</SpanishTermName><SpanishTermDefinition><DefinitionText>Ingrediente activo de un medicamento que se usa para aliviar ciertos efectos secundarios que causa el tratamiento con opioides (analgésicos similares a la morfina), como el estreñimiento (heces duras y secas), picazón y flujo bajo de orina. La metilnaltrexona se une a los receptores opioides fuera del cerebro y puede bloquear los efectos secundarios de los opioides sin afectar su capacidad de aliviar el dolor. La metilnaltrexona es un tipo de antagonista del receptor periférico de opioides.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-03-10</DateFirstPublished><DateLastModified>2008-07-18</DateLastModified></GlossaryTerm>
